These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32615125)

  • 1. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 3. Excessive outlier removal may result in cut points that are not suitable for immunogenicity assessments.
    Kubiak RJ; Zhang J; Ren P; Yang H; Roskos LK
    J Immunol Methods; 2018 Dec; 463():105-111. PubMed ID: 30312600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity assay cut point determination using nonparametric tolerance limit.
    Zhang J; Li W; Roskos LK; Yang H
    J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical Approaches for Establishing Appropriate Immunogenicity Assay Cut Points: Impact of Sample Distribution, Sample Size, and Outlier Removal.
    Garlits J; McAfee S; Taylor JA; Shum E; Yang Q; Nunez E; Kameron K; Fenech K; Rodriguez J; Torri A; Chen J; Sumner G; Partridge MA
    AAPS J; 2023 Apr; 25(3):37. PubMed ID: 37016171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
    Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
    J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Alternative Data Transformation Approach for ADA Cut Point Determination: Why Not Use a Weibull Transformation?
    Jordan G; Staack RF
    AAPS J; 2021 Aug; 23(5):97. PubMed ID: 34389881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate.
    Motulsky HJ; Brown RE
    BMC Bioinformatics; 2006 Mar; 7():123. PubMed ID: 16526949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.
    Devanarayan V; Smith WC; Brunelle RL; Seger ME; Krug K; Bowsher RR
    AAPS J; 2017 Sep; 19(5):1487-1498. PubMed ID: 28733862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical methods and tool for cut point analysis in immunogenicity assays.
    Zhang L; Zhang JJ; Kubiak RJ; Yang H
    J Immunol Methods; 2013 Mar; 389(1-2):79-87. PubMed ID: 23305975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population.
    Tan CY; Steeno GS; You Z; Gaitonde P; Cai CH; Kamerud J; Gorovits B; Baltrukonis DJ
    AAPS J; 2020 Jan; 22(2):19. PubMed ID: 31900604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size consideration for immunoassay screening cut-point determination.
    Zhang J; Zhang L; Yang H
    J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of applications of biological products for drug interference of immunogenicity assays.
    Wang YM; Fang L; Zhou L; Wang J; Ahn HY
    Pharm Res; 2012 Dec; 29(12):3384-92. PubMed ID: 22903525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of analytical detection concepts to immunogenicity testing.
    Klakamp SL; Lu H; Tabrizi M; Funelas C; Roskos LK; Coleman D
    Anal Chem; 2007 Nov; 79(21):8176-84. PubMed ID: 17922557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical approaches for the determination of cut points in anti-drug antibody bioassays.
    Schaarschmidt F; Hofmann M; Jaki T; Grün B; Hothorn LA
    J Immunol Methods; 2015 Mar; 418():84-100. PubMed ID: 25733352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.